Vericel (VCEL) reported $276M in revenue for fiscal 2025, +16.5% year on year. That ranks #2524 by revenue among 2853 SEC filers and #255 in Healthcare. Net income was $16.5M, a net margin of 6.0%. Revenue has grown 19.8% a year on average since 2016 ($54.4M then). The fiscal 2025 balance sheet shows $488M in total assets, $100M in cash and $16.9M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $276M | +16.5% | FY20252025-12-31 |
| Gross profitGrossProfit | $206M | +19.5% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $11.0M | +144.4% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $16.5M | +59.4% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $51.9M | −10.8% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $27.2M | −57.5% | FY20252025-12-31 |
| Total assetsAssets | $488M | +12.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $355M | +21.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $100M | +34.3% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $16.9M | +81.2% | FY20172017-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $68.4M | −$6.3M | Open → |
| Q2 20262026-06-30 | $77.5M | $2.2M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Vericel Corp
- Ticker
- VCEL
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0000887359
Filings
- 10-QJul 30, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Xeris BiopharmaXERS | $292M | $554,000 |
| Aurinia PharmaceuticalsAUPH | $283M | $287M |
| Adaptive BiotechnologiesADPT | $277M | −$59.5M |
| VericelVCEL | $276M | $16.5M |
| HarrowHROW | $272M | −$5.1M |
| Viemed HealthcareVMD | $270M | $15.4M |
| Vireo GrowthVREOF | $269M | −$68.1M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Vericel — Key figures |url=https://companiesranked.com/en/company/vericel |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Vericel — Key figures. CompaniesRanked. https://companiesranked.com/en/company/vericelBibTeX
@misc{companiesranked-en-company-vericel-2026,
author = {{CompaniesRanked}},
title = {{Vericel — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/vericel}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-012013 · February 26, 2026
{{cite web |title=Vericel — Key figures — 10-K (0001628280-26-012013) |url=https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/vcel-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.